Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109330 · ClinicalTrials.gov registry record · Phase 3
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,116
- Enrollment target
NCT00109330 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,116 participants.
The verdict
NCT00109330, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,116 participants
- Enrollment target
Study Summary
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
Interventions
- BIOLOGICAL Combined diphtheria, tetanus, acellular pertussis vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,116 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109330
The ClinicalTrials.gov registry entry for NCT00109330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combined diphtheria, tetanus, acellular pertussis vaccine is the first listed.
NCT00109330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109330 about?
NCT00109330 is a clinical study titled "A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine". This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
What is the current status of trial NCT00109330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,116 participants. The study started on 2002-11. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00109330?
The interventions under investigation include: Combined diphtheria, tetanus, acellular pertussis vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109330?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.